McKesson and CoverMyMeds

Overview

McKesson Corporation (NYSE: MCK) is the largest pharmaceutical distributor in North America, handling one-third of U.S. drug volume. CoverMyMeds, acquired in 2017 for $1.1 billion, is the dominant U.S. electronic prior authorization platform with ~90% ePA market share. Together with Biologics by McKesson (specialty pharmacy), McKesson 3PL, and patient support services (RxCrossroads legacy), they form the Prescription Technology Solutions (RxTS) segment.

RxTS is McKesson’s strategically most important segment: while it represents only 1.4% of consolidated revenue ($5.2B of $359B), it generates approximately 16% of consolidated adjusted operating profit at ~19% margins — the company’s highest-margin business. McKesson has reaffirmed an 11-12% long-term adjusted segment operating profit growth target for RxTS.

See CoverMyMeds for a dedicated deep dive on the ePA platform and its competitive dynamics. (Source: raw/mckesson_rxts_profile.md)

Services & Capabilities

U.S. Pharmaceutical Distribution (Core Business)

• Wholesale distribution of branded, generic, specialty, biosimilar, and OTC medications
• Serves pharmacies, health systems, and specialty providers
• ~1/3 of U.S. drug volume
• National distribution infrastructure — largest pharmaceutical footprint in the U.S.

RxTS Segment Components

1. CoverMyMeds — See dedicated profile

• Electronic prior authorization (~90% U.S. ePA market share)
• Patient access & affordability technology (copay cards, PAP enrollment)
• Pharma manufacturer services (650+ brands, 95% of therapeutic areas)
• Network: 1M+ providers, 50K+ pharmacies, 350+ EHR integrations, 96% payer coverage

2. McKesson Third-Party Logistics (3PL)

• 2B+ units shipped annually (ambient, refrigerated, frozen, controlled)
• 99.98% inventory and order accuracy
• Title model: McKesson purchases product using own distribution licenses — ideal for smaller biopharma lacking state-level licenses, enabling faster market entry
• Non-title (agency) model: McKesson acts as manufacturer’s agent
• Supports CAR-T and cell/gene therapy ultra-cold chain logistics
• Largest revenue contributor within RxTS by dollar volume (lower margin than tech services)

3. Biologics by McKesson (Specialty Pharmacy)

• Headquartered in Cary, NC; 30+ years operating history (acquired 2016 for ~$600M)
• Oncology-focused (primary), rare disease, cell & gene therapy
• 200+ therapies including 100+ oral medications
• 25+ exclusive therapies — must-have status for certain drugs
• Integral to LDNs for 115+ additional therapies
• $64M+ in patient financial assistance facilitated (2024)
• InspiroGene by McKesson — cell and gene therapy logistics and clinical management
• Clinical model: pharmacists, nurses, case managers; risk-based care program, adherence monitoring, REMS management

4. Patient Support Services (RxCrossroads Legacy)

• Acquired from CVS Health in 2017 for $735M
• CoverMyMeds Patient Support Center: 355,000+ patients served (2023)
• Hub services: benefits investigation, financial assistance, SP coordination, adherence support
• AMP (Access for More Patients): Joint CoverMyMeds + RxCrossroads solution embedding hub enrollment into ePA workflow at point of prescribing — “upstream” vs. traditional “downstream” hub model
• Pilot studies: reimbursement steps completed in 11 days on average vs. weeks through manual hubs

5. CoverMyMeds Pharmacy Dispensing Network

• Commercial and non-commercial dispensing for manufacturer programs
• PAP, bridge programs, limited distribution medications
• Closes the loop from authorization to dispense

Competitive Position

RxTS Segment Financial Performance

Metric	FY2025	FY2024	FY2023	YoY Growth (FY25)
Revenue	$5.2B	$4.8B	$4.4B	+9%
Adj. Operating Profit	$1.0B	$837M	$682M	+15%
Adj. Operating Margin	~19.2%	~17.4%	~15.5%	+180bps

FY2026 Q1 (June 2025): Revenue $1.4B (+16%); adjusted operating profit $269M (+21%). Accelerating.

McKesson Overall

Segment	FY2025 Revenue	FY2025 Adj. Op. Profit	Margin
U.S. Pharmaceutical	$327.7B	$3.7B	1.1%
RxTS	$5.2B	$1.0B	19.2%
Medical-Surgical	$11.4B	$1.0B	8.8%
International	$14.7B	$428M	2.9%

Vertical Integration Advantage

McKesson is the only company connecting: distribution (US Pharma) —> patient access technology (CoverMyMeds) —> specialty pharmacy (Biologics) —> hub services (RxCrossroads) —> oncology practice network (US Oncology Network). No competitor has this full stack from a distribution perspective — including PBM-integrated specialty pharmacies.

Key Strengths

1. Highest-margin segment — ~19% adjusted operating margins vs. 1.1% for distribution
2. Favorable mix shift — Operating profit growing 2-3x faster than revenue (tech services outpacing 3PL volume)
3. Specialty drug tailwind — Specialty spending growing 10-12% annually drives both 3PL volumes and access/affordability tech demand
4. Durable growth target — 11-12% long-term adjusted operating profit CAGR consistently met or exceeded
5. Biologics LDN position — 25+ exclusive therapies, 115+ LDN participations create must-have status for newly launched drugs

Key Risks

1. CoverMyMeds concentration — Majority of high-margin profit from CoverMyMeds’ pharma manufacturer services; ePA market position erosion would disproportionately impact
2. Biologics scale limitations — Cannot match PBM-integrated specialty pharmacies on volume; dependent on maintaining LDN access
3. 3PL commoditization — Competitive, lower-margin business; Cencora and Cardinal Health offer similar services
4. Regulatory uncertainty — CMS-0057-F mandates could open ePA market to new interoperable entrants

Recent Developments

Date	Development
FY2025	RxTS revenue $5.2B (+9%); adjusted operating profit $1.0B (+15%)
2025 Q1	Acquired RxLightning (digital specialty enrollment) and FastAuth (automated PA)
2025	Controlling interest in Florida Cancer Specialists’ Core Ventures and PRISM Vision Holdings (ophthalmology)
2025	100M+ medication access events, $10.9B+ patient savings, 12M+ prescriptions saved from abandonment
Aug 2025	AmeriHealth discontinued CoverMyMeds ePA — transitioning to Surescripts
Mar 2026	CoverMyMeds launched Specialty Access and Affordability Solutions — integrated medical PA, pharmacy PA, BI, and enrollment in EHR. Initial: oncology and ophthalmology
FY2026 Q1	RxTS revenue $1.4B (+16%); adjusted operating profit $269M (+21%)
Jun 2025	Biologics: PIQRAY, VIJOICE became exclusive therapies

Client & Partner Ecosystem

• 650+ pharma brands; 50K+ pharmacies; 1M+ providers; payers covering 96% of prescriptions
• 350+ EHR integrations (Epic, Oracle Health/Cerner, NextGen, etc.)
• US Oncology Network — community oncology practices
• Specialty pharmacy partners and LDN participation across 115+ therapies

Technology Platform

• CoverMyMeds Platform — ePA, hub services, affordability integrated in EHR workflows (see dedicated profile)
• RxBenefit Clarity — Real-time benefit and cost transparency
• AMP: Access for More Patients — Upstream specialty enrollment
• RxLightning (2025) — Digital-first specialty enrollment
• FastAuth (2025) — Automated end-to-end PA
• InspiroGene — Cell and gene therapy orchestration

Therapeutic Focus

Broad (95% of therapeutic areas). Specialty strength in oncology (Biologics, US Oncology Network), rare disease/orphan drugs, cell & gene therapy (InspiroGene), biosimilars, and ophthalmology (PRISM Vision acquisition). March 2026 Specialty Access launch targeting oncology and ophthalmology first.

Target Customers

Pharma/biopharma manufacturers (primary revenue source for RxTS), specialty pharmacies, health systems, retail pharmacies, providers, payers/PBMs. The full ecosystem connects distribution clients to technology and services clients, creating cross-sell flywheel.

Sources

• Raw RxTS profile: mckesson_rxts_profile.md
• Raw CoverMyMeds profile: covermymeds_profile.md
• Raw vendor database
• McKesson.com
• CoverMyMeds.health
• McKesson FY2025 Results
• McKesson FY2026 Q1 SEC Filing
• Biologics by McKesson
• McKesson 3PL Overview
• RxCrossroads Acquisition (Pharmaceutical Commerce)